液相色谱-串联质谱法同时测定人血浆中奈必洛尔和缬沙坦的固定剂量复方制剂及其在药代动力学研究中的应用
Simultaneous determination of fixed dose combination of nebivolol and valsartan in human plasma by liquid chromatographic-tandem mass spectrometry and its application to pharmacokinetic study.
作者信息
Selvan P Senthamil, Gowda K Veeran, Mandal U, Solomon W D Sam, Pal T K
机构信息
Bioequivalence Study Centre, Department of Pharmaceutical Technology, Jadavpur University, Kolkata 700 032, India.
出版信息
J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Oct 15;858(1-2):143-50. doi: 10.1016/j.jchromb.2007.08.016. Epub 2007 Aug 22.
A rapid, sensitive and accurate liquid chromatographic-tandem mass spectrometry method is described for the simultaneous determination of nebivolol and valsartan in human plasma. Nebivolol and valsartan were extracted from plasma using acetonitrile and separated on a C18 column. The mobile phase consisting of a mixture of acetonitrile and 0.05 mM formic acid (50:50 v/v, pH 3.5) was delivered at a flow rate of 0.25 ml/min. Atmospheric pressure ionization (API) source was operated in both positive and negative ion mode for nebivolol and valsartan, respectively. Selected reaction monitoring mode (SRM) using the transitions of m/z 406.1-->m/z 150.9; m/z 434.2-->m/z 179.0 and m/z 409.4-->m/z 228.1 were used to quantify nebivolol, valsartan and internal standard (IS), respectively. The linearity was obtained over the concentration range of 0.01-50.0 ng/ml and 1.0-2000.0 ng/ml and the lower limits of quantitation were 0.01 ng/ml and 1.0 ng/ml for nebivolol and valsartan, respectively. This method was successfully applied to the pharmacokinetic study of fixed dose combination (FDC) of nebivolol and valsartan formulation product after an oral administration to healthy human subjects.
本文描述了一种快速、灵敏且准确的液相色谱-串联质谱法,用于同时测定人血浆中的奈必洛尔和缬沙坦。采用乙腈从血浆中提取奈必洛尔和缬沙坦,并在C18柱上进行分离。流动相由乙腈和0.05 mM甲酸(50:50 v/v,pH 3.5)的混合物组成,流速为0.25 ml/min。大气压电离(API)源分别以正离子和负离子模式运行,用于奈必洛尔和缬沙坦的检测。分别采用m/z 406.1→m/z 150.9、m/z 434.2→m/z 179.0和m/z 409.4→m/z 228.1的选择反应监测模式(SRM)对奈必洛尔、缬沙坦和内标(IS)进行定量。在0.01 - 50.0 ng/ml和1.0 - 2000.0 ng/ml的浓度范围内获得线性关系,奈必洛尔和缬沙坦的定量下限分别为0.01 ng/ml和1.0 ng/ml。该方法成功应用于健康人体受试者口服奈必洛尔和缬沙坦固定剂量复方制剂产品后的药代动力学研究。